Solid Biosciences Inc. Common Stock

SLDBNASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
6.70 USD
↘ 0.54 (7.46%)AT CLOSE (11:59 AM EDT)
6.90
↗ 0.20 (2.99%)
POST MARKET (AS OF 05:57 PM EDT)
Post Market
AS OF 05:57 PM EDT
6.90
↗ 0.20 (2.99%)
🔴Market: CLOSED
Open?$7.17
High?$7.20
Low?$6.63
Prev. Close?$7.24
Volume?701.7K
Avg. Volume?1.1M
VWAP?$6.80
Rel. Volume?0.63x
Bid / Ask
Bid?$5.81 × 100
Ask?$7.70 × 100
Spread?$1.89
Midpoint?$6.76
Valuation & Ratios
Market Cap?659.6M
Shares Out?98.4M
Float?66.8M
Float %?67.9%
P/E Ratio?N/A
P/B Ratio?1.76
EPS?-$1.95
Dividend?0.00%
Ex-Dividend?N/A

SLDB is currently priced at $6.70. Our models show a "Neutral" technical signal alongside a "Neutral" fundamental rating. Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingBiotech - Drug Development›Rare Disease Therapeutics
Employees
121
Market Cap
659.6M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.solidbio.com
Listed
2018-01-25
Address
500 RUTHERFORD AVENUE
CHARLESTOWN, MA 02129
Phone: 617-337-4680
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
94
Momentum?
50
Short Sent.?
34
Piotroski F-Score?0/9Weak
Altman Z-Score?4.26Safe
Confidence?45%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?13.64%High
Short Interest?9.1M
Days to Cover?6.8
Free Float66.8M
Avg Daily Volume1.3M
Settlement Date2026-05-15
Financial Health
Current Ratio?13.08Strong
Quick Ratio?13.08Strong
Cash Ratio?9.81Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
81
1.76CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.9CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-51.3%WEAK▾
ROA?
S&P
3
-45.4%WEAK▾
Cash Flow & Enterprise
FCF?$-172861000
Enterprise Value?$362.5M
Fundamentals ratios updated end of day
MarketsMoversWatchlist